Advances in genetics have allowed scientists to identify genes (biomarkers) that are linked with certain diseases. To translate these great scientific findings into real-world products (personalized medicine) for those who need them, clinical trials play an essential and important role. In this talk, we discuss some new families of adaptive designs that genetics information and other biomarkers can be incorporated in treatment selection. Advantages of the proposed methods are demonstrated through both theoretical and numerical studies. Some further statistical issues are also discussed.